2026 / 03

DOI: 10.24075/brsmu.2026.034
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Chemokine (C-C motif) ligand 19 and interleukin 23 in patients with post lyme disease syndrome and neurological involvement

Baranova NS , Ostapenko YaS , Baranov AA , Ovsyanikova LA , Spirin NN , Rechkina OP , Zolotavkina SS , Vdovenko OV , Semechkin NV
About authors

Yaroslavl State Medical University, Yaroslavl, Russia

Correspondence should be addressed: Natalia Sergeevna Baranova
Revolutsionnaya str., 5, Yaroslavl, 150000, Russia; ur.liam@sn_avonarab

About paper

Funding: the work was supported by the Ministry of Social Communications and Scientific and Technological Development of the Yaroslavl Region (grant agreement No. 26NP/2024 of December 25, 2024).

Author contribution: Baranova NS, Ostapenko YaS, Baranov AA, Spirin NN — study planning and design; Ostapenko YaS, Ovsyanikova LA, Rechkina OP, Zolotavkina SS, Vdovenko OV, Semechkin NV — data collection and research; Baranova NS, Ostapenko YaS, Baranov AA — data analysis; Baranova NS, Ostapenko YaS, Baranov AA — article authoring.

Compliance with ethical standards: the study was approved by the Ethics Committee of Yaroslavl State Medical University (Minutes No. 63 of September 14, 2023). All patients signed a voluntary informed consent.

Received: 2026-05-18 Accepted: 2026-06-13 Published online: 2026-06-26
|
  1. Klinicheskie rekomendacii. Bolezn' Lajma u vzroslyh. 2025. Dostupno po ssylke: http://medelement.com/disease/bolezn'-lajma-u-vzroslyh-kr-rf-2025/19081 (data obrashcheniya: 10.03.2026). Russian.
  2. Rudakova SA, Teslova OE, Mutalinova NE, Rudakov NV, Penevskaya NA, Kuzmenko YuF, et al. Epidemiologicheskaya situaciya po iksodovym kleshchevym borreliozam v Rossijskoj Federacii v 2010–2024 gg. i prognoz na 2025 g. Problemy osobo opasnyh infekcij. 2025; 2: 39– 46. DOI: 10.21055/0370-1069-2025-2-39-46. Russian.
  3. Steere AC, Strle F, Wormser GP. Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016; 2: 16090. DOI: 10.1038/nrdp.2016.90. Erratum in: Nat Rev Dis Primers. 2017; 3: 17062. DOI: 10.1038/nrdp.2017.62.
  4. Radolf JD, Strle K, Lemieux JE, Strle F. Lyme Disease in Humans. Curr Issues Mol Biol. 2021; 42: 333–84. DOI: 10.21775/cimb.042.333.
  5. Schwartz AM, Kugeler KJ, Nelson CA, Marx GE, Hinckley AF. Use of commercial claims data for evaluating trends in Lyme disease diagnoses, United States, 2010–2018. Emer Infect Dis. 2021; 27 (2): 499–507. DOI: 10.3201/eid2702.202728.
  6. Steinbrink A, Brugger K, Margos G, Kraiczy P, Klimpel S. The evolving story of Borrelia burgdorferi sensu lato transmission in Europe. Parasitol. Res. 2022; 121 (3): 781–803. DOI: 10.1007/ s00436-022-07445-3.
  7. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43: 1089–134. DOI: 10.1086/508667.
  8. Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015; 61: 1800–6. DOI: 10.1093/cid/civ735.
  9. Shor S, Green C, Szantyr B, Phillips S, Liegner K, Burrascano JJ Jr, et al. Chronic Lyme disease: an evidence-based definition by the ILADS working group. Antibiotics (Basel). 2019; 8: 269. DOI: 10.3390/antibiotics8040269.
  10. Zafar K, Azuama OC, Parveen N. Current and emerging approaches for eliminating Borrelia burgdorferi and alleviating persistent Lyme disease symptoms. Front Microbiol. 2024; 15: 1459202. DOI: 10.3389/fmicb.2024.1459202.
  11. Steere AC. Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses. J Clin Invest. 2020; 130 (5): 2148–51. DOI: 10.1172/JCI138062.
  12. Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One. 2014; 9 (4): e93243. DOI: 10.1371/journal.pone.0093243.
  13. Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, et al. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol. 2016; 23 (9): 757–66. DOI: 10.1128/CVI.00071-16.
  14. Strle K, Stupica D, Drouin EE, Steere AC, Strle F. Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans. Clin Infect Dis. 2014; 58 (3): 372–80. DOI: 10.1093/cid/cit735.
  15. Hernández SA, Ogrinc K, Korva M, Kastrin A, Bogovič P, Rojko T, et al. Associated of persistent symptoms after Lyme Neuroborreliosis and increased levels of interferon-α in blood. Emerg Infect Dis. 2023; 29 (6): 1091–101. DOI: 10.3201/eid2906.221685.
  16. Adkison H, Embers ME. Lyme disease and the pursuit of a clinical cure. Front Med (Lausanne). 2023; 10: 1183344. DOI: 10.3389/fmed.2023.1183344.
  17. Raffetin A, Saunier A, Bouiller K, Caraux-Paz P, Eldin C, Gallien S, at al. Unconventional diagnostic tests for Lyme borreliosis: a systematic review. Clin Microbiol Infect. 2020; 26 (1): 51–59. DOI: 10.1016/j.cmi.2019.06.033.
  18. Baranova NS, Ostapenko YaS, Ovsyannikova LA, Spirin NN, Baranov AA, Bykanova MA. Clinical characteristics of neurological involvement in post-treatment Lyme disease syndrome: part 1. RMJ. 2026; 4: 7–12. DOI: 10.32364/2225-2282-2026-4-2. Russian.
  19. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2009; 6: 42. DOI: 10.1186/1742-2094-6-42.
  20. Girgis AA, Cimbro R, Yang T, Rebman AW, Sewell T, Villegas de Flores D, et al. Aberrant T-cell phenotypes in a cohort of patients with post-treatment Lyme disease. Front Immunol. 2025; 16: 1607619. DOI: 10.3389/fimmu.2025.1607619.
  21. Eckman EA, Pacheco-Quinto J, Herdt AR, Halperin JJ. Neuroimmunomodulators in neuroborreliosis and Lyme encephalopathy. Clin Infect Dis. 2018; 67 (1): 80–88. DOI: 10.1093/cid/ciy019.
  22. Baranova NS, Ovsyannikova LA, Ostapenko YaS, Spirin NN, Baranov AA, Gris MS, et al. Cytokine levels in patients with multiple sclerosis and chronic neuroborreliosis. Neurology, Neuropsychiatry, Psychosomatics. 2024; 16 (Suppl.2): 57–64. DOI: 10.14412/2074-2711-2024-2S-57-64. Russian.
  23. Uhde M, Ajamian M, Li X, Wormser GP, Marques A, Alaedini A. Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis. 2016; 63: 1399–404. DOI: 10.1093/cid/ciw599.
  24. Rudakova SA, Rudakov NV, Shtrek SV, Teslova OE, Kaneshova NE. Genovidovaya harakteristika kleshchevyh borreliozov v Rossii. Fundamental'naya i klinicheskaya medicina. 2021; 6 (3): 94–99. DOI: 10.23946/2500-0764-2021-6-3-94-99. Russian.
  25. Tveita A, Murphy SL, Holter JC, Kildal AB, Michelsen AE, Lerum TV, et al. High circulating levels of the homeostatic chemokines CCL19 and CCL21 predict mortality and disease severity in COVID-19. J Infect Dis. 2022; 226 (12): 2150–60. DOI: 10.1093/infdis/jiac313.
  26. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10–20 years after active Lyme disease. Clin Infect Dis. 2001; 33 (6): 780–5. DOI: 10.1086/322669.
  27. Blum LK, Adamska, J Z, Martin DS, Rebman, AW, Elliott SE, Cao RRL, et al. Robust B cell responses predict rapid resolution of Lyme disease. Front. Immunol. 2018; 9: 1634. DOI: 10.3389/fimmu.2018.01634.
  28. Bockenstedt LK, Wooten RM, Baumgarth N. Immune response to Borrelia: lessons from Lyme Disease spirochetes. Curr Issues Mol Biol. 2021; 42: 145–190. DOI: 10.21775/cimb.042.145.
  29. Nakano K, Whitehead GS, Lyons-Cohen MR, Grimm SA, Wilkinson CL, Izumi G, et al. Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. 2024; 153 (2): 487–502.e9. DOI: 10.1016/j.jaci.2023.10.024.
  30. Yan Y, Chen R, Wang X, Hu K, Huang L, Lu M, et al. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. Front Cell Dev Biol. 2019; 7: 212. DOI: 10.3389/fcell.2019.00212.
  31. Bielecki B, Jatczak-Pawlik I, Wolinski P, Bednarek A, Glabinski A. Central nervous system and peripheral expression of CCL19, CCL21 and their receptor CCR7 in experimental model of multiple sclerosis. Arch Immunol Ther Exp (Warsz). 2015; 63 (5): 367–76. DOI: 10.1007/s00005-015-0339-9.
  32. Krumbholz M, Theil D, Steinmeyer F, Cepok S, Hemmer B, Hofbauer M, et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol. 2007; 190 (1–2): 72– 9. DOI: 10.1016/j.jneuroim.2007.07.024.
  33. Hastey CJ, Ochoa J, Olsen KJ, Barthold SW, Baumgarth N. MyD88- and TRIF-independent induction of type I interferon drives naive B cell accumulation but not loss of lymph node architecture in Lyme disease. Infect Immun. 2014; 82: 1548 –8. DOI: 10.1128/IAI .00969-13.
  34. Li Y, Yu X, Ma Y, Hua S. IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy? Cytokine. 2019; 120: 78–84. DOI: 10.1016/j.cyto.2019.02.018.
  35. Kuwabara T, Tanaka Y, Ishikawa F, Kondo M, Sekiya H, Kakiuchi T. CCR7 ligands up-regulate IL-23 through PI3-kinase and NF-κ B pathway in dendritic cells. J Leukoc Biol. 2012; 92 (2): 309–18. DOI: 10.1189/jlb.0811415.
  36. Gutierrez-Hoffmann M, Fan J, O'Meally RN, Cole RN, Florea L, Antonescu C, et al. The Interaction of Borrelia burgdorferi with Human Dendritic Cells: Functional Implications. J Immunol. 2023; 211 (4): 612–25. DOI: 10.4049/jimmunol.2300235.
  37. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8 (3): 239–45. DOI: 10.1038/ni1443.
  38. Helble JD, McCarthy JE, Sawden M, Starnbach MN, Hu LT. The PD-1/PD-L1 pathway is induced during Borrelia burgdorferi infection and inhibits T cell joint infiltration without compromising bacterial clearance. PLoS Pathog. 2022; 18 (10): e1010903. DOI: 10.1371/journal.ppat.1010903.
  39. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016; 44 (5): 989–1004. DOI: 10.1016/j.immuni.2016.05.001.
  40. Lochhead RB, Strle K, Arvikar SL, Weis JJ, Steere AC. Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol. 2021; 17 (8): 449–61. DOI: 10.1038/s41584-021-00648-5.
  41. Harden JL, Egilmez NK. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012; 41 (6–7): 738– 64. DOI: 10.3109/08820139.2012.676122.
  42. Thompson D, Sorenson J, Greenmyer J, Brissette CA, Watt JA. The Lyme disease bacterium, Borrelia burgdorferi, stimulates an inflammatory response in human choroid plexus epithelial cells. PLoS One. 2020; 15 (7): e0234993. DOI: 10.1371/journal.pone.0234993.
  43. Barwe SP, Skay A, McSpadden R, Huynh TP, Langhans SA, Inge LJ, et al. Na,K-ATPase β-subunit cis homo-oligomerization is necessary for epithelial lumen formation in mammalian cells. J Cell Sci. 2012; 125 (Pt 23): 5711–20. DOI: 10.1242/jcs.108795.
  44. Laaker C, Baenen C, Kovács KG, Sandor M, Fabry Z. Immune cells as messengers from the CNS to the periphery: the role of the meningeal lymphatic system in immune cell migration from the CNS. Front Immunol. 2023; 14: 1233908. DOI: 10.3389/fimmu.2023.1233908.
  45. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012; 4 (147): 147ra111. DOI: 10.1126/scitranslmed.3003748.
  46. Cai Y, Zhang Y, Leng S, Ma Y, Jiang Q, Wen Q, et al. The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: A vicious cycle. Neurobiol Dis. 2024; 192: 106426. DOI: 10.1016/j.nbd.2024.106426.
  47. Mader S, Brimberg L. Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells. 2019; 8 (2): 90. DOI: 10.3390/cells8020090.
  48. Morley SC. T cells go with the flow: aquaporin 4 is required for full T-cell activation. J Leukoc Biol. 2023; 113 (6): 541–3. DOI: 10.1093/jleuko/qiad041.
  49. Nicosia M, Lee J, Beavers A, Kish D, Farr GW, McGuirk PR, et al. Water channel aquaporin 4 is required for T cell receptor mediated lymphocyte activation. J Leukoc Biol. 2023; 113 (6): 544–54. DOI: 10.1093/jleuko/qiad010.
  50. Skucas VA, Mathews IB, Yang J, Cheng Q, Treister A, Duffy AM, et al. Impairment of select forms of spatial memory and neurotrophin-dependent synaptic plasticity by deletion of glial aquaporin-4. J Neurosci. 2011; 31: 6392–7. DOI: 10.1523/JNEUROSCI.6249-10.2011.
  51. Zhang J, Li Y, Chen ZG, Dang H, Ding JH, Fan Y, et al. Glia protein aquaporin-4 regulates aversive motivation of spatial memory in Morris water maze. CNS Neurosci Ther. 2013; 19: 937–44. DOI: 10.1111/cns.12191.
  52. Nemat-Gorgani M, Jensen MA, Davis RW. Glymphatic system dysregulation as a key contributor to myalgic encephalomyelitis/ chronic fatigue syndrome. Int J Mol Sci. 2025; 26 (23): 11524. DOI: 10.3390/ijms262311524.
  53. Turpaev KT. Transkripcionnyj faktor KLF2 i ego rol' v regulyacii vospalitel'nyh processov. Obzor. Biohimiya, 2020; 85 (1): 64–79 DOI: 10.31857/S0320972520010054. Russian.
  54. Xu S, Liu Y, Ding Y, Luo S, Zheng X, Wu X, et al. The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. Signal Transduct Target Ther. 2021; 6 (1): 266. DOI: 10.1038/s41392-021-00690-5.
  55. Lei L, Chen M, Wang C, Jiang X, Li Y, Wang W, et al. Trichostatin D as a Novel KLF2 Activator Attenuates TNFα-Induced Endothelial Inflammation. Int J Mol Sci. 2022; 23 (21): 13477. DOI: 10.3390/ijms232113477.
  56. Jha P, Das H. KLF2 in Regulation of NF-κB-Mediated Immune Cell Function and Inflammation. Int J Mol Sci. 2017; 18 (11): 2383. DOI: 10.3390/ijms18112383.
  57. Tsui C, Heyden L, Wen L, Gago da Graça C, Potemkin N, Frolov A, et al. Lymph nodes fuel KLF2-dependent effector CD8+ T cell differentiation during chronic infection and checkpoint blockade. Nat Immunol. 2025; 26 (10): 1752–65. DOI: 10.1038/s41590-025-02276-7.